BICYCLE THERAPEUTICS LTD
NASDAQ: BCYC (Bicycle Therapeutics plc)
Last update: yesterday, 6:21AM7.38
0.30 (4.24%)
| Previous Close | 7.08 |
| Open | 7.14 |
| Volume | 267,767 |
| Avg. Volume (3M) | 277,590 |
| Market Cap | 511,481,952 |
| Price / Sales | 25.55 |
| Price / Book | 0.740 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -703.66% |
| Diluted EPS (TTM) | -3.16 |
| Quarterly Revenue Growth (YOY) | -48.90% |
| Total Debt/Equity (MRQ) | 1.12% |
| Current Ratio (MRQ) | 14.86 |
| Operating Cash Flow (TTM) | -180.22 M |
| Levered Free Cash Flow (TTM) | -108.88 M |
| Return on Assets (TTM) | -21.69% |
| Return on Equity (TTM) | -37.07% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Bicycle Therapeutics plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.25 |
|
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.46% |
| % Held by Institutions | 93.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fcpm Iii Services B.V. | 30 Jun 2025 | 3,452,330 |
| Westfield Capital Management Co Lp | 30 Jun 2025 | 2,780,491 |
| Long Focus Capital Management, Llc | 30 Jun 2025 | 1,317,293 |
| Candriam S.C.A. | 30 Jun 2025 | 1,172,387 |
| Bnp Paribas Asset Management Holding S.A. | 30 Jun 2025 | 1,041,456 |
| Tybourne Capital Management (Hk) Ltd | 30 Jun 2025 | 993,743 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 44.00 (Oppenheimer, 496.21%) | Buy |
| Median | 19.00 (157.45%) | |
| Low | 10.00 (JMP Securities, 35.50%) | Buy |
| Average | 23.00 (211.65%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 7.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 12 Aug 2025 | 10.00 (35.50%) | Buy | 7.22 |
| Morgan Stanley | 12 Aug 2025 | 13.00 (76.15%) | Hold | 7.22 |
| Oppenheimer | 11 Aug 2025 | 44.00 (496.21%) | Buy | 7.46 |
| RBC Capital | 17 Jul 2025 | 25.00 (238.75%) | Buy | 8.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Aug 2025 | Announcement | Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results |
| 03 Jun 2025 | Announcement | Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |